Oscar Estupinan
Overview
Explore the profile of Oscar Estupinan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
76
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Estupinan O, Rey V, Tornin J, Murillo D, Gallego B, Huergo C, et al.
Biomed Pharmacother
. 2023 Apr;
162:114627.
PMID: 37018985
Osteosarcomas are frequently associated to a poor prognosis and a modest response to current treatments. EC-8042 is a well-tolerated mithramycin analog that has demonstrated an efficient ability to eliminate tumor...
2.
Gallego B, Murillo D, Rey V, Huergo C, Estupinan O, Rodriguez A, et al.
Int J Mol Sci
. 2022 Jun;
23(12).
PMID: 35742867
Bone sarcomas have not shown a significant improvement in survival for decades, due, in part, to the development of resistance to current systemic treatments, such as doxorubicin. To better understand...
3.
Ortal A, Rodriguez A, Solis-Hernandez M, de Prado M, Rey V, Tornin J, et al.
Sci Rep
. 2022 Apr;
12(1):6911.
PMID: 35484295
Sarcomas are mesenchymal cancers which often show an aggressive behavior and patient survival largely depends on an early detection. In last years, much attention has been given to the fact...
4.
Estupinan O, Niza E, Bravo I, Rey V, Tornin J, Gallego B, et al.
J Nanobiotechnology
. 2021 Sep;
19(1):267.
PMID: 34488783
Background: Sarcomas comprise a group of aggressive malignancies with very little treatment options beyond standard chemotherapy. Reposition of approved drugs represents an attractive approach to identify effective therapeutic compounds. One...
5.
Estupinan O, Rendueles C, Suarez P, Rey V, Murillo D, Moris F, et al.
J Clin Med
. 2021 Apr;
10(7).
PMID: 33806182
Sarcomas are aggressive tumors which often show a poor response to current treatments. As a promising therapeutic alternative, we focused on mithramycin (MTM), a natural antibiotic with a promising anti-tumor...
6.
Menendez S, Rey V, Martinez-Cruzado L, Victoria Gonzalez M, Morales-Molina A, Santos L, et al.
Cancers (Basel)
. 2020 Apr;
12(4).
PMID: 32295077
Stemness in sarcomas is coordinated by the expression of pluripotency factors, like SOX2, in cancer stem cells (CSC). The role of SOX2 in tumor initiation and progression has been well...
7.
Rey V, Menendez S, Estupinan O, Rodriguez A, Santos L, Tornin J, et al.
J Clin Med
. 2019 Apr;
8(4).
PMID: 30987403
For the cancer genomics era, there is a need for clinically annotated close-to-patient cell lines suitable to investigate altered pathways and serve as high-throughput drug-screening platforms. This is particularly important...
8.
Estupinan O, Santos L, Rodriguez A, Fernandez-Nevado L, Costales P, Perez-Escuredo J, et al.
Int J Cancer
. 2018 Dec;
145(1):254-266.
PMID: 30575954
Cytotoxic drugs like doxorubicin remain as the most utilized agents in sarcoma treatment. However, advanced sarcomas are often resistant, thus stressing the need for new therapies aimed to overcome this...
9.
Tornin J, Hermida-Prado F, Padda R, Victoria Gonzalez M, Alvarez-Fernandez C, Rey V, et al.
Neoplasia
. 2017 Dec;
20(1):44-56.
PMID: 29190494
Deregulated SRC/FAK signaling leads to enhanced migration and invasion in many types of tumors. In myxoid and round cell liposarcoma (MRCLS), an adipocytic tumor characterized by the expression of the...